|Mr. Mark K. Oki||Sr. VP, CFO & Chief Accounting Officer||473.61k||N/A||1969|
|Mr. John L. Slebir||Sr. VP of Bus. Devel., Gen. Counsel & Sec.||642.07k||N/A||1965|
|Dr. Santosh T. Varghese||Chief Medical Officer||508.64k||N/A||1970|
|Mr. John P. Amos||CEO & Director||N/A||N/A||1967|
|Mr. Kenneth Suh||Pres||N/A||N/A||1976|
VIVUS, Inc. operates as a specialty pharmaceutical company primarily in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body-mass index of 30 or greater (obese patients) or 27 or greater (overweight patients) in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus, or high cholesterol. It also provides PANCREAZE to treat exocrine pancreatic insufficiency due to cystic fibrosis or other conditions; and STENDRA/SPEDRA, an oral phosphodiesterase type 5 inhibitor for erectile dysfunction. In addition, the company is developing Qsymia, which has completed Phase II clinical study for treating various diseases, including obstructive sleep apnea, diabetes, and nonalcoholic steatohepatitis; and VI-0106 that has completed Phase IIa study to treat patients with pulmonary arterial hypertension. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation; Menarini Group; Sanofi; Metuchen Pharmaceuticals, LLC; Selten Pharma, Inc.; Alvogen Malta Operations (ROW) Ltd; and Janssen Pharmaceuticals, Inc. VIVUS, Inc. was founded in 1991 and is headquartered in Campbell, California.
VIVUS, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.